Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Semaglutide Cost in 2026: Ozempic, Wegovy, Insurance
articleOzempic and Wegovy list at $900–$1,865 a month, but few patients pay that. This guide walks through every semaglutide cost lever: manufacturer savings cards, NovoCare direct self-pay, commercial insurance, Medicare Part D's obesity exclusion, and how brand-name semaglutide compares to tirzepatide on cash-pay access. Includes a 2026 reality check on what happened to compounded semaglutide.
Ozempic Cost 2026: List Price, Insurance, Self-Pay
articleThis Ozempic-specific cost guide walks the list price, commercial insurance, Medicare Part D, and the 2026 NovoCare self-pay ladder, plus why the diabetes-versus-weight-loss distinction drives most of what you actually pay.